Jieqiong Liu1,2, Kai Chen3,4, Wen Jiang5, Kai Mao6, Shunrong Li3, Min Ji Kim7, Qiang Liu3, Lisa K Jacobs8. 1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Yanjiang West Road 107#, Guangzhou, 510120, China. liujieqiong01@163.com. 2. Department of Surgery, Johns Hopkins University School of Medicine, 600 N. Wolfe Street/Blalock 607, Baltimore, MD, 21287, USA. liujieqiong01@163.com. 3. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Yanjiang West Road 107#, Guangzhou, 510120, China. 4. Department of Surgery, Johns Hopkins University School of Medicine, 600 N. Wolfe Street/Blalock 607, Baltimore, MD, 21287, USA. 5. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, USA. 6. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of General Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. 7. Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 8. Department of Surgery, Johns Hopkins University School of Medicine, 600 N. Wolfe Street/Blalock 607, Baltimore, MD, 21287, USA. ljacob14@jhmi.edu.
Abstract
PURPOSE: To study the impact of hormone receptor (HR)- and human epidermal growth factor receptor 2 (HER2)-defined subtypes on survival of inflammatory breast cancer (IBC), and to determine whether sensitivity to neoadjuvant chemotherapy (NAC) varies with subtypes in a large IBC population. METHODS: We analyzed 593 IBCs with known HR/HER2 statuses between 2010 and 2011 from National Cancer Database. We compared pathologic complete response (pCR) rates among four molecular subtypes by Chi-square test. Overall survival (OS) was compared among four subtypes and patients with or without pCR using log-rank test. Multivariate Cox model was performed to identify the impact of molecular subtype and other prognostic factors on OS. RESULTS: Of the 593 patients included, 231 (39.0 %) patients had HR+/HER2- tumors, 98 (16.5 %) had HR+/HER2+ disease, 112 (18.9 %) were HR-/HER2 + patients, and 152 (25.6 %) had triple-negative subtype. The pCR rates differed significantly by subtype (P < 0.001): HR-/HER2+ showed the highest, and HR+/HER2- exhibited the lowest. Multivariate analysis showed that triple-negative and HR+/HER2- IBCs had significantly worse survival compared with HR+/HER2+ or HR-/HER2+ subtype (P < 0.01 for all comparisons). Additional factors associated with worse OS included more comorbidities, lack or incomplete surgical resection, absence of radiotherapy, lack of hormone therapy, and more advanced stage. CONCLUSIONS: IBC is an aggressive heterogeneous disease with distinct molecular subtypes associated with differential outcomes and sensitivities to NAC. Unlike in noninflammatory breast cancer, in IBC HR + disease was not associated with favorable prognosis. Triple-negative and HR+/HER2- subtypes are independent predictors for suboptimal OS in IBC.
PURPOSE: To study the impact of hormone receptor (HR)- and human epidermal growth factor receptor 2 (HER2)-defined subtypes on survival of inflammatory breast cancer (IBC), and to determine whether sensitivity to neoadjuvant chemotherapy (NAC) varies with subtypes in a large IBC population. METHODS: We analyzed 593 IBCs with known HR/HER2 statuses between 2010 and 2011 from National Cancer Database. We compared pathologic complete response (pCR) rates among four molecular subtypes by Chi-square test. Overall survival (OS) was compared among four subtypes and patients with or without pCR using log-rank test. Multivariate Cox model was performed to identify the impact of molecular subtype and other prognostic factors on OS. RESULTS: Of the 593 patients included, 231 (39.0 %) patients had HR+/HER2- tumors, 98 (16.5 %) had HR+/HER2+ disease, 112 (18.9 %) were HR-/HER2 + patients, and 152 (25.6 %) had triple-negative subtype. The pCR rates differed significantly by subtype (P < 0.001): HR-/HER2+ showed the highest, and HR+/HER2- exhibited the lowest. Multivariate analysis showed that triple-negative and HR+/HER2- IBCs had significantly worse survival compared with HR+/HER2+ or HR-/HER2+ subtype (P < 0.01 for all comparisons). Additional factors associated with worse OS included more comorbidities, lack or incomplete surgical resection, absence of radiotherapy, lack of hormone therapy, and more advanced stage. CONCLUSIONS: IBC is an aggressive heterogeneous disease with distinct molecular subtypes associated with differential outcomes and sensitivities to NAC. Unlike in noninflammatory breast cancer, in IBC HR + disease was not associated with favorable prognosis. Triple-negative and HR+/HER2- subtypes are independent predictors for suboptimal OS in IBC.
Entities:
Keywords:
Chemotherapy response; Inflammatory breast cancer; Molecular subtype; National Cancer Database; Overall survival
Authors: Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808
Authors: Jing Li; Ana M Gonzalez-Angulo; Pamela K Allen; Tse K Yu; Wendy A Woodward; Naoto T Ueno; Anthony Lucci; Savitri Krishnamurthy; Yun Gong; Melissa L Bondy; Wei Yang; Jie S Willey; Massimo Cristofanilli; Vicente Valero; Thomas A Buchholz Journal: Oncologist Date: 2011-12-06
Authors: Ana M Gonzalez-Angulo; Jennifer K Litton; Kristine R Broglio; Funda Meric-Bernstam; Ronjay Rakkhit; Fatima Cardoso; Florentia Peintinger; Emer O Hanrahan; Aysegul Sahin; Merih Guray; Denis Larsimont; Francesco Feoli; Heidi Stranzl; Thomas A Buchholz; Vicente Valero; Richard Theriault; Martine Piccart-Gebhart; Peter M Ravdin; Donald A Berry; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver Journal: Breast Cancer Res Treat Date: 2012-06-26 Impact factor: 4.872
Authors: Shaheenah Dawood; Naoto T Ueno; Vicente Valero; Wendy A Woodward; Thomas A Buchholz; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo; Massimo Cristofanilli Journal: Cancer Date: 2010-11-29 Impact factor: 6.860
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Hugo Arias-Pulido; Ashley Marie Cimino-Mathews; Nabila Chaher; Clifford Ray Qualls; Nancy Joste; Cecile Colpaert; Jonathan Douglas Marotti; Mary Dickinson Chamberlin; Maxwell Gabriel Foisey; Eric Robert Prossnitz; Leisha Ann Emens; Steven Fiering Journal: Breast Cancer Res Treat Date: 2021-09-20 Impact factor: 4.872
Authors: Toshiaki Iwase; Kenichi Harano; Hiroko Masuda; Kumiko Kida; Kenneth R Hess; Ying Wang; Luc Dirix; Steven J Van Laere; Anthony Lucci; Savitri Krishnamurthy; Wendy A Woodward; Rachel M Layman; François Bertucci; Naoto T Ueno Journal: BMC Cancer Date: 2020-05-18 Impact factor: 4.430
Authors: D J P van Uden; M C van Maaren; L J A Strobbe; P Bult; J J van der Hoeven; S Siesling; J H W de Wilt; C F J M Blanken-Peeters Journal: Breast Cancer Res Date: 2019-10-17 Impact factor: 6.466